Bessemer Group Inc. Has $32.19 Million Stake in Repligen Corporation (NASDAQ:RGEN)

Bessemer Group Inc. raised its position in Repligen Corporation (NASDAQ:RGEN - Free Report) by 1.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 253,014 shares of the biotechnology company's stock after buying an additional 4,325 shares during the period. Bessemer Group Inc. owned 0.45% of Repligen worth $32,193,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wealthquest Corp acquired a new position in shares of Repligen in the 1st quarter worth approximately $264,000. Oppenheimer Asset Management Inc. raised its position in Repligen by 12.1% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 19,684 shares of the biotechnology company's stock valued at $2,505,000 after purchasing an additional 2,117 shares during the last quarter. Ausbil Investment Management Ltd acquired a new position in Repligen in the first quarter worth $135,000. Center for Financial Planning Inc. boosted its stake in Repligen by 110.3% in the first quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock worth $47,000 after purchasing an additional 193 shares in the last quarter. Finally, State of Alaska Department of Revenue grew its holdings in shares of Repligen by 2.8% during the first quarter. State of Alaska Department of Revenue now owns 6,104 shares of the biotechnology company's stock worth $776,000 after purchasing an additional 165 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Evercore ISI began coverage on shares of Repligen in a research report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price target on the stock. Canaccord Genuity Group reduced their target price on shares of Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a research report on Wednesday, April 16th. JPMorgan Chase & Co. dropped their price objective on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th. Barclays initiated coverage on Repligen in a report on Tuesday. They set an "overweight" rating and a $150.00 price objective on the stock. Finally, HC Wainwright reissued a "buy" rating and issued a $180.00 target price on shares of Repligen in a research note on Monday, May 5th. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $172.83.

Repligen Trading Down 0.5%

Shares of Repligen stock traded down $0.65 during trading hours on Friday, hitting $123.56. The company's stock had a trading volume of 851,478 shares, compared to its average volume of 730,932. The company has a market capitalization of $6.94 billion, a PE ratio of -274.58, a price-to-earnings-growth ratio of 3.56 and a beta of 1.10. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.79 and a quick ratio of 5.79. The stock has a 50 day moving average of $128.10 and a 200 day moving average of $141.03. Repligen Corporation has a 12 month low of $102.97 and a 12 month high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.35 by $0.04. The firm had revenue of $169.17 million for the quarter, compared to the consensus estimate of $163.65 million. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The business's quarterly revenue was up 10.4% on a year-over-year basis. During the same period last year, the company posted $0.28 EPS. Analysts predict that Repligen Corporation will post 1.72 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.